Inhibition of ERK restores both GSK3β activity and levels of protein synthesis in Tsc2−/− cells, thus identifying ERK as a candidate therapeutic target for the treatment of tuberous sclerosis. The gene discussed is MAPK1; the disease is tuberous sclerosis.